StockData

BrilliA vs Ping An Biomedical

BRIA and PASW side by side, both in apparel and other finished products made from fabrics and similar materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BRIA and PASW compare

BrilliA grew revenue faster over the last twelve months (−23.1% versus −61.0% for Ping An Biomedical).

BrilliA keeps more of each dollar of sales as profit, with a net margin of −0.03% compared with −37.6% at Ping An Biomedical.

Ping An Biomedical scores higher on the StockData Score (2 against 1 for BrilliA), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBRIAPASW
Size and price
Share price$1.35$1.53
Change, 1 year−25.0%−94.1%
Beta (5Y)0.46–
Employees2247
StockData Score
Total score12 (better)
Valuation score00
Growth score00
Performance score00
Health score12 (better)
Dividend score00
Growth
Revenue growth (TTM)−23.1% (better)−61.0%
Net income growth (TTM)−101%–
EPS growth (TTM)−108%–
Profitability
Gross margin14.3% (better)2.8%
Operating margin–−43.1%
Net margin−0.03% (better)−37.6%
FCF margin0.34%–
Return on equity–−38.6%
Return on invested capital–−29.2%
Financial health
Debt / equity–0.13
Interest coverage–−47.9×
Current ratio2.232.54 (better)
Piotroski F-score33
Ownership
Held by institutions0.00%–
Held by insiders72.9%10.3%
Short interest, % of float0.15%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.